CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04832438
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:47.062348+00:00
Published At: 2022-02-22T00:00:00+00:00
Record Updated At: 2022-02-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Salivary Gland Carcinoma", "Adenoid Cystic Carcinoma", "Salivary Gland Cancer", "Salivary Gland Neoplasms"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-02-22"
protocolSection.identificationModule.nctId: "NCT04832438"
protocolSection.identificationModule.officialTitle: "Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3\u03b2) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.